Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $23000.0.

  • Aclaris Therapeutics' Capital Expenditures changed N/A to $23000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $87000.0, marking a year-over-year decrease of 8451.96%. This contributed to the annual value of $121000.0 for FY2024, which is 9075.63% down from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Capital Expenditures is $23000.0.
  • Over the past 5 years, Aclaris Therapeutics' Capital Expenditures peaked at $553000.0 during Q1 2023, and registered a low of -$14000.0 during Q2 2024.
  • For the 5-year period, Aclaris Therapeutics' Capital Expenditures averaged around $158533.3, with its median value being $135000.0 (2024).
  • Per our database at Business Quant, Aclaris Therapeutics' Capital Expenditures surged by 240000.0% in 2021 and then plummeted by 10606.06% in 2024.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Capital Expenditures stood at $200000.0 in 2021, then crashed by 47.5% to $105000.0 in 2022, then soared by 320.0% to $441000.0 in 2023, then crashed by 103.17% to -$14000.0 in 2024, then soared by 264.29% to $23000.0 in 2025.
  • Its last three reported values are $23000.0 in Q3 2025, $21000.0 for Q2 2025, and $43000.0 during Q1 2025.